title: Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
abstract: 5-Fluorouracil (5-FU) and 5-fluorodeoxyuridine (FdUrd, floxuridine) have activity in multiple tumors, and both agents undergo intracellular processing to active metabolites that disrupt RNA and DNA metabolism. These agents cause imbalances in deoxynucleotide triphosphate levels and the accumulation of uracil and 5-FU in the genome, events that activate the ATR- and ATM-dependent checkpoint signaling pathways and the base excision repair (BER) pathway. Here, we assessed which DNA damage response and repair processes influence 5-FU and FdUrd toxicity in ovarian cancer cells. These studies revealed that disabling the ATM, ATR, or BER pathways using small inhibitory RNAs did not affect 5-FU cytotoxicity. In stark contrast, ATR and a functional BER pathway protected FdUrd-treated cells. Consistent with a role for the BER pathway, the poly(ADP-ribose) polymerase (PARP) inhibitors ABT-888 (veliparib) and AZD2281 (olaparib) markedly synergized with FdUrd but not with 5-FU in ovarian cancer cell lines. Furthermore, ABT-888 synergized with FdUrd far more effectively than other agents commonly used to treat ovarian cancer. These findings underscore differences in the cytotoxic mechanisms of 5-FU and FdUrd and suggest that combining FdUrd and PARP inhibitors may be an innovative therapeutic strategy for ovarian tumors.
authors: Divisions of Oncology Research, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA.
authors: Amelia M
authors: AM
authors: Huehls
authors: Jill M
authors: JM
authors: Wagner
authors: Catherine J
authors: CJ
authors: Huntoon
authors: Liyi
authors: L
authors: Geng
authors: Charles
authors: C
authors: Erlichman
authors: Anand G
authors: AG
authors: Patel
authors: Scott H
authors: SH
authors: Kaufmann
authors: Larry M
authors: LM
authors: Karnitz
references: Oncogene. 2006 Aug 31;25(39):5359-69
references: 16619043
references: Oncogene. 2008 Dec 11;27(58):7223-34
references: 18806825
references: Nature. 2001 May 24;411(6836):494-8
references: 11373684
references: Mol Cancer Ther. 2006 Aug;5(8):1935-43
references: 16928813
references: Mol Cancer Res. 2009 Jun;7(6):897-906
references: 19470598
references: Nat Rev Cancer. 2003 May;3(5):330-8
references: 12724731
references: Cancer. 1991 Sep 1;68(5):995-8
references: 1833043
references: Nat Rev Cancer. 2010 Apr;10(4):293-301
references: 20200537
references: Cancer Res. 1968 Oct;28(10):1976-81
references: 5696930
references: Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
references: 18594563
references: Am J Hum Genet. 2004 Oct;75(4):654-60
references: 15309689
references: Mol Cancer Ther. 2009 May;8(5):1015-25
references: 19383854
references: J Clin Oncol. 1992 Dec;10(12):1933-42
references: 1453207
references: J Virol. 2004 Aug;78(16):8931-4
references: 15280503
references: Gynecol Oncol. 1996 Jun;61(3):395-402
references: 8641622
references: Mol Cancer Ther. 2007 Apr;6(4):1406-13
references: 17431119
references: J Appl Toxicol. 2009 May;29(4):308-16
references: 19115314
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Cancer Res. 2005 Jul 15;65(14):6394-400
references: 16024643
references: In Vitro. 1978 Sep;14(9):787-94
references: 721103
references: J Cancer Res Clin Oncol. 2004 Oct;130(10):561-6
references: 15449185
references: J Cell Biochem. 2008 Sep 1;105(1):245-54
references: 18543256
references: Cancer Res. 2010 Nov 1;70(21):8642-50
references: 20841485
references: Cell Mol Life Sci. 2009 Mar;66(6):981-93
references: 19153658
references: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15387-92
references: 14657349
references: Adv Enzyme Regul. 1984;22:27-55
references: 6382953
references: Cancer Chemother Pharmacol. 1991;28(4):241-50
references: 1831736
references: Cell Cycle. 2006 Sep;5(17):1983-8
references: 16931916
references: Mol Cell Biol. 2004 Oct;24(19):8356-65
references: 15367657
references: Cancer Res. 2004 Sep 15;64(18):6588-94
references: 15374972
references: Cancer Chemother Pharmacol. 1995;37(1-2):32-8
references: 7497594
references: Mol Pharmacol. 2009 Jul;76(1):208-14
references: 19403702
references: Anticancer Drugs. 2010 Mar;21(3):277-87
references: 20075715
references: Semin Oncol. 2005 Dec;32(6 Suppl 9):S97-100
references: 16399443
references: Cancer Chemother Pharmacol. 1991;28(1):69-73
references: 1828191
references: J Clin Oncol. 2009 Jun 1;27(16):2705-11
references: 19364967
references: Ann Oncol. 2006 Sep;17(9):1404-11
references: 16788003
references: Oncogene. 2005 Feb 17;24(8):1403-11
references: 15608676
references: Mol Cancer Ther. 2008 Jan;7(1):133-42
references: 18202016
references: Oncogene. 2003 Dec 8;22(56):9063-74
references: 14663485
references: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):889-900
references: 15279774
references: Clin Cancer Res. 2008 Aug 15;14(16):5131-41
references: 18698031
references: Cell Mol Life Sci. 2009 Mar;66(5):788-99
references: 18979208
references: Nucleic Acids Res. 2008 Oct;36(17):5678-94
references: 18772227
references: Mol Biol Cell. 2009 Sep;20(17):3801-9
references: 19570909
references: Oncogene. 2008 Oct 27;27(50):6522-37
references: 18955977